This study represents the first comprehensive in silico exploration of the binding potential of radioiodinated anastrozole ([125I]anastrozole) and epirubicin ([125I]epirubicin) against the AKT1 enzyme, a critical target in breast cancer therapy. This evidence concerns the gene AKT1 and breast carcinoma.